Our news

/Our news/
6 10, 2016

Therapeutic angiogenesis is induced by UCX® in a murine model of hindlimb ischemia

October 6th, 2016|Sem categoria|

UCX® have the potential to promote a full range of events leading to tissue regeneration and homeostasis as demonstrated in induced hindlimb ischemia (HLI) in animal models. UCX® was shown to enhance angiogenesis in vitro via a paracrine effect. Importantly, [...]

6 10, 2016

Self-assembled 3D spheroids and hollow-fibre bioreactors improve UCX®-derived hepatocyte-like cell maturation in vitro

October 6th, 2016|Sem categoria|

3D cultures of human stem cell-derived hepatocyte-like cells (HLCs) have emerged as promising models for short- and long-term maintenance of hepatocyte phenotype in vitro cultures by better resembling the in vivo environment of the liver and consequently increase the translational [...]

27 04, 2016

ECBio sees its grant for UCX®-PAD development approved

April 27th, 2016|Sem categoria|

ECBio’s SI I&DT grant for the clinical development of UCX® in the area of Peripheral Artery Disease (PAD) – involving a Phase I/IIa clinical trial, has been approved by the PT2020 programme. Congratulations ECBio.

31 03, 2016

ECBio’s Patent on the Optimised and Defined Method For Isolation And Preservation Of Precursor Cells From Human Umbilical Cord has been granted in Europe.

March 31st, 2016|Sem categoria|

ECBio's European patent application Nº 08807881, and Pub.Nº EP2203555, on the OPTIMISED AND DEFINED METHOD FOR ISOLATION AND PRESERVATION OF PRECURSOR CELLS FROM HUMAN UMBILICAL CORD has been granted in Europe. Congratulations ECBio.

11 11, 2015

Dr. Helder Cruz explains the UCX® advantages over BM-MSCs on national TV news broadcast

November 11th, 2015|Sem categoria|

Watch here.

11 09, 2015

The ClinUCX R&D project reveals extraordinary advancements on the effects of UCX® application in a PAD model

September 11th, 2015|Sem categoria|

ECBio´s work in straight collaboration with AIDFM/FMUL, shows for the first time that UCX® can stimulate angiogenesis and arteriogenesis, and thereby improve blood perfusion in the ischemic limbin of experimentally induced hind limb ischemia in vivo. These results suggest that [...]

11 09, 2015

The ClinUCX R&D project reveals excellent long-term UCX® cardioprotective effect after MI

September 11th, 2015|Sem categoria|

A long term evaluation of the UCX® cardioprotective effect after MI induction in vivo has revealed an even more drastic functional improvemnt of the performance of the ischemic myocardium when compared to the controls. A robust microultrasound system, with higher [...]

18 06, 2015

ECBio reveals remarkable differences between UCX® and BM-MSCs

June 18th, 2015|Sem categoria|

ECBio´s latest research on UCX® potency and mechanism of action has revealed relevant differences between MSCs from different origins. To elucidate the potency differences observed between UCX® and BM-MSCs, gene expression related to immune modulation was analysed in both cell [...]

18 06, 2015

ECBio will be at the ISSCR annual meeting: An Unveiling of Stem Cell Innovation

June 18th, 2015|Sem categoria|

ECBio will be at the ISSCR annual meeting"An Unveiling of Stem Cell Innovation", Stockholm 24-27 June. Meet us at the posters sessions and discuss UCX® immunomodulatory and agiogenic potency and how it may, or may not, be affected by cryopreservation. [...]

8 05, 2015

ECBio and its collaborators at FFUL and INEB have shown how to improve the therapeutic potency of UCX

May 8th, 2015|Sem categoria|

Congratulations ECBio. Stem Cell Research & Therapy.2015, 6:90 DOI: 10.1186/s13287-015-0082-5